Psilocybin Therapy

Watch the Panel recently hosted at the UW Law School Center for Law in Science & Global Health on the Right To Try effort as a means to open access to Psilocybin Therapy featuring AIMS Institute Co-director Dr. Sunil Aggarwal.

RECENT DEVELOPMENTS REGARDING ACCESS TO PSILOCYBEN THERAPY, DECEMBER 14, 2020
This conference discussed recent innovative efforts to remove barriers to access to psilocybin. In recent years there has been increasing interest in use of psychedelics for relief of anxiety and depression at the end of life, treatment of depression, and post-traumatic stress disorder. Our speakers discussed recent developments from legal, medical, mental health and advocacy perspectives.

About The Author

admin

Latest Blog Posts

A Holistic Solution to Health Disparities: Naturopathic Medicine and Culturally Competent Care 

A Holistic Solution to Health Disparities: Naturopathic Medicine and Culturally Competent Care 

Healthcare Disparities in African American Communities African Americans continue to face significant disparities in healthcare. From higher mortality rates for chronic conditions like cancer and heart disease to underdiagnosis of autoimmune disorders, these inequities stem from systemic racism, implicit bias, and a lack of cultural sensitivity among providers. Studies show that Black patients are less likely to receive adequate pain management and more likely to feel unheard or dismissed during medical visits. These disparities erode trust in the healthcare system and lead to poorer outcomes and avoidable suffering. For many, navigating the system can feel isolating and disempowering, leaving them ...

Read More
At AIMS Institute we prescribe low dose oral naltrexone for ‘long COVID’

At AIMS Institute we prescribe low dose oral naltrexone for ‘long COVID’

A recent paper in the Frontiers in Medicine states that An underutilized intervention for long  COVID is low dose naltrexone, which has an established safety profile for a variety of conditions. ‘Naltrexone is a non-selective opioid antagonist currently approved by the US Food and Drug Administration (FDA) for the treatment of alcohol and opioid dependence and is prescribed at 50–150 mg daily. At doses below 5 mg, it is considered low-dose naltrexone (LDN), exhibits anti-inflammatory and analgesic properties, and has been used off-label to reduce severity of symptoms in conditions such as fibromyalgia, multiple sclerosis, complex regional pain syndrome, myalgic encephalomyelitis/chronic fatigue ...

Read More
Unusual Suspects

Unusual Suspects

Psychedelic Therapies Gain New Advocates Texas Law Magazine Written by Robin Berghaus. Art by Matthieu Bourel Published November 6, 2024 Marcus Capone served seven combat tours as a Navy SEAL — including missions with SEAL Team Six, the nation’s preeminent counterterrorism unit — before being medically retired in 2013. For years, he struggled to find effective treatments for his traumatic brain injuries, depression, and post-traumatic stress disorder. Capone tried antidepressants, talk therapy, hyperbaric oxygen therapy, transcranial magnetic stimulation, and he visited several brain clinics. Nothing worked. When Capone’s life began falling apart, he considered suicide. His wife was just as ...

Read More
Call Us Text Us
Skip to content